Sovaldi Forecast to be Biggest Selling Drug in 2020 as EvaluatePh?arma Extends Consensus Sales Forecasts

Life science market intelligence company, Evaluate, Ltd, has extended its exclusive consensus sales forecast analyses within its service platforms from 2018 to 2020. Evaluate’s consensus forecasts are derived by its expert analysts using the un-weighted average of up to six of the leading equity research forecasts.

Both EvaluatePharma and EvaluateMedTech contain the new forecast information. In addition, new detail on minimum, maximum and median forecasts enables more in-depth analysis of the future direction of the pharma, biotech and medtech sectors.

An analysis using the extended consensus forecasts reveals that Sovaldi will top the list of biggest selling drugs in 2020. For further information read the full story by EP Vantage, Evaluate’s editorial team, that also reveals a surprising entrant to the elite tier of top selling drugs. “The Biggest Drugs 2020” article is available at www.evaluategroup.com/BiggestDrugs2020.  

"Given its history-making launch it is no surprise that Gilead’s juggernaut Sovaldi is forecast to become the biggest drug in 2020, the big question will be how long this drug can hang onto the top spot," said Lisa Urquhart, EP Vantage editor.

Evaluate’s premier annual report, “EvaluatePharma World Preview 2014: Outlook to 2020”, will highlight the new consensus forecast data. The report will examine the impact of patent expirations and include analysis on R&D spend, as well as the leading products and companies by therapeutic area and geographies. Evaluate will release the report during the 2014 BIO Convention taking place 23–26 June in San Diego.